Getting away from glucose: fanning the flames of obesity-induced inflammation
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The complex processes linking obesity to its deleterious health consequences are finally being unraveled. Inflammation is receiving increased attention for its potential role in the pathogenesis of disorders ranging from insulin resistance and type 2 diabetes (T2D) to steatohepatitis and cardiovascular disease (CVD). Recent back-to-back studies show that obesity perturbs inflammatory gene networks, and hint at causal relationships between inflammation and disease traits associated with the metabolic syndrome. Approaches used in these studies are distinct from classical genome-wide associational studies or tissue-specific mRNA expression profiling, as they rely on ‘neural networks’ and high-powered computational methods to interconnect genetic, genomic and environmental data into a ‘causal’ model. Gene expression was assessed as a quantitative trait to predict which features of obesity promote disease. The first study revealed a tendency towards activation of an inflammation network in adipose tissue of Icelandic subjects with a higher body mass index1. Parallel results were found in the second study, which similarly analyzed adipose tissue and liver from obese and control mice2. A major strength of this approach is that individual state changes can be considered in the context of other changes occurring not only in the tissue being examined, but simultaneously in other tissues, and in the context of genetics, environmental determinants, and even over time. As a word of caution, however, these are early days in systems biology, and findings are limited by the quantity and accuracy of the data used to construct the networks. The relatively unbiased approach used in these studies affirms a role for inflammation in the pathogenesis of metabolic diseases. The approach should also provide new biomarkers for obesity and related metabolic diseases. An additional major promise of such systems biology approaches is in their application to drug discovery. The administration of a drug provides a single perturbation that should influence multiple components of the system. The approach should provide valuable information about mechanisms of action, not only for the drug’s beneficial effects but also for side effects that may limit utility. Identification of new biomarkers for assessing response to a drug should also provide avenues for personalized medicine, by tailoring interventions to an individual’s underlying disease mechanisms. How do these new findings fit the larger, emerging picture of obesity-induced inflammation? Epidemiological evidence relating inflammation to T2D and obesity has existed since the 1950s3, but was not considered in terms of pathogenesis until the 1990s. The list of markers shown to be elevated in obesity includes white blood cell count and plasma concentrations of sialic acid, C-reactive protein (CRP), TNF-α, and IL-6, among other factors3,4, and the list continues to grow. TNF-α was hypothesized to mediate obesity-induced inflammation, because it is produced in adipose tissue and neutralization in mice curbed insulin resistance5. However, TNF-α neutralization trials in humans were negative6, which dampened enthusiasm not only for TNF-α as a drug target in T2D, but for the ‘inflammation hypothesis’ of T2D. New discoveries continued to rekindle interest in this area of investigation despite these ongoing debates. The discovery that obesity also activates intracellular pathways, including IKKβ/NF-κB and JNK7,8, added fuel to the inflammatory hypothesis. Upregulation of the IKKβ/NF-κB axis leads to the excess production of multiple potential mediators of inflammation, whereas JNK activation impinges on insulin signaling through phosphorylation of serine residues of IRS-1. Stimuli potentially activating both IKKβ/NF-κB and JNK in obesity can be separated into extracellular ligands, such as proinflammatory cytokines TNF-α, IL-1β and IL-6 or fatty acids binding to TLRs -- and intracellular stimuli such ER or oxidative stress and ceramides3. Determining which processes initiate obesity-induced inflammation is an active area of investigation. The discovery of macrophages in obese adipose tissue was another milestone towards better understanding obesity-induced inflammation9,10. Macrophages appear to accumulate in obese fat in response to adipocyte stress and death, possibly due to insufficient angiogenesis and hypoxia. Although incompletely understood, the macrophages may participate in the development insulin resistance, T2D and CVD through production of proinflammatory cytokines, chemokines, and other factors. Inhibition of NF-κB or JNK in macrophages improves insulin resistance11,12. Importantly for patients with T2D or CVD, these recent discoveries promise potential new avenues for treatment. Despite the earlier failures with TNF-α blockers, it now appears that inflammation will provide viable therapeutic targets. Two approaches are already being validated in clinical trials, anti-inflammatory salicylates and IL-1 blockade. The salicylates are atypical members of the non-steroidal anti-inflammatory class of drugs, which target NF-κB as opposed to the cyclooxygenase enzymes, Cox1 and Cox2. Salsalate, a salicylate prodrug, has been shown to have glucose lowering efficacy in small trials13, with larger TINSAL-T2D trials ongoing (www.TINSAL-T2D.org). The recombinant IL-1 receptor antagonist anakinra, currently approved for use in rheumatoid arthritis, also improves glycemia in patients with T2D14. IL-1 blockade and salsalate are both likely to improve β cell function and insulin resistance, although anakinra reportedly targets β cells and salsalate effects have focused on insulin sensitivity13,14. While it is too early to say whether salicylate or anakinra will go the distance, these approaches have already served to validate inflammation as a pharmacological target in T2D. Moreover, these approaches are vastly different from one another, as anakinra is an injected biological that binds extracellular IL-1 proteins, whereas salicylate (salsalate) is an orally active small molecule that acts in cells to inhibit transcription. This suggests that numerous nodes or points within inflammation networks may be targeted in diabetes - which is good news, as the therapeutic area of inflammation is rich in molecular targets that have already received great attention from the pharmaceutical industry. Of course salsalate and anakinra target inflammation systemically, while potential targets identified by the back-to-back studies of Schadt and Stefansson and colleagues are restricted to adipose tissue. Unless the studies are expanded to other tissues, which is both feasible and a strength of the approach, the potential targets they identify will be in adipose tissue. Modulation of these targets could have systemic effects and even β cell effects, but this needs to be shown. The authors pointed out that several genes already related to obesity, Zfp90, C3ar1, Hsd11b1 and Tgfbr2, were identified by and thus validated their approach. They also studied 3 additional genes, Lpl, Lactb and Ppm1l, which they identify as “previously unknown obesity genes,” although lipoprotein lipase (Lpl) is certainly well known to researchers in the field. The independent ablation of each of these genes leads to an overweight or obese phenotype. Additional studies will determine whether these are bona fide drug targets or ‘just’ research tools. But it is certain that these types of systems biology, network analysis approaches will prove to be invaluable in the hunt for safer and more efficacious drugs that are tailored to obese subjects and patients with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inflammation lies at the heart of many of these processes, and pathways involving NF-κB (see e.g. http://www.nf-kb.org/) are especially core here”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Shoelson and Goldfine 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Self-citationA central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884
Self-citationInterleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
IKK-β links inflammation to obesity-induced insulin resistance
Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z.-W., Long, J. M., Wynshaw-Boris, A., Poli, G., Olefsky, J., & Karin, M. (2005) · Nature Medicine · doi:10.1038/nm1185 · Cited by 1,773
Genetics of gene expression and its effect on disease
Emilsson, V., Thorleifsson, G., Zhang, B., Leonardson, A. S., Zink, F., Zhu, J., Carlson, S., Helgason, A., Walters, G. B., Gunnarsdottir, S., et al. (2008) · Nature · doi:10.1038/nature06758 · Cited by 1,296
Is Type II diabetes mellitus a disease of the innate immune system?
Pickup, J. C., & Crook, M. A. (1998) · Diabetologia · doi:10.1007/s001250051058 · Cited by 1,041
Cited by
Items 101–106 of 106
Earpina, S. (2013) · Louisiana State University · doi:10.31390/gradschool_theses.1770
Fróes, F. T. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Villalba, S. N. S., Paguay, L. E. C., Jácome, M. Á. E., & Arizala, J. F. C. (2024) · SCT Proceedings in Interdisciplinary Insights and Innovations. · doi:10.56294/piii2024341
Suffys, C. R., Ferrazoli, R., & Sharma, E. (2025) · American Journal of BioMedicine · doi:10.18081/2333-5106/2025.13/19
Yu, S. J., Oh, H., Kim, D. J., Jang, M., Yoon, K. C., Noh, H., Lee, Y. B., Cho, E. J., Lee, J.-H., Kim, Y. J., et al. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01201-5
Iron deficiency and obesity : are the two linked?
Kaçar, H. K. (2019) · Nottingham ePrints (University of Nottingham)
Metadata
- Authors
- Shoelson, S. E., & Goldfine, A. B.
- Affiliations
- Joslin Diabetes Center (US)
- Venue
- Nature Medicine
- Published
- 2009-04
- Volume
- 15
- Issue
- 4
- Pages
- 373-374
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC4097148
- OpenAlex
- W2062840218
- Cited by
- 98
- References
- 14
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 4 · 2015: 7 · 2014: 4 · 2013: 11 · 2012: 18
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p50hl083813-05)
- National Heart, Lung, and Blood Institute (P50-HL083813)
- National Institute of Diabetes and Digestive and Kidney Diseases (RC4DK090792, U01DK074556, R01DK095327, R01DK045943, R01DK051729, R37DK051729, R01DK073547, R01DK043123, P30DK036836)
- National Center for Research Resources (M01RR001032, M01RR002635)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Skin Diseases and Diabetes
- Keywords
- obesity, inflammation, glucose, obesity-associated inflammation
- MeSH terms
- Adipose Tissue, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fatty Liver, Humans, Inflammation, Insulin Resistance, Obesity, Gene Expression, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.